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AbsTrACT
background Metaphyseal dysplasia without 
hypotrichosis (MDWH) is a rare form of chondrodysplasia 
with no extraskeletal manifestations. MDWH is caused 
by RMRP mutations, but it is differentiated from the 
allelic condition cartilage- hair hypoplasia (cHH), which in 
addition to chondrodysplasia is characterised by thin hair, 
immunodeficiency and increased risk of malignancy. the 
long- term outcome of MDWH remains unknown.
Objective We diagnosed severe agranulocytosis in a 
subject with RMRP mutations and normal hair. Based 
on this observation, we hypothesised that MDWH may, 
similar to cHH, associate with immune deficiency and 
malignancy.
Methods We collected clinical and laboratory data for 
a cohort of 80 patients with RMRP mutations followed 
for over 30 years and analysed outcome data for those 
with features consistent with MDWH.
results in our cohort, we identified 10 patients with 
skeletal but no extraskeletal features during preschool 
age. eight of these patients developed malignancy 
or clinically significant immunodeficiency during 
follow- up. two of them died during chemotherapy 
for malignancy. at the time of the first extraskeletal 
manifestation, patients were school aged, 20, 43 and 
50 years old. laboratory signs of immunodeficiency 
(impaired lymphocyte proliferative responses) were 
demonstrated in four patients before the onset of 
symptoms. the patient outside this cohort, who had 
RMRP mutations, skeletal dysplasia, normal hair and 
severe agranulocytosis at 18 years of age, underwent 
haematopoietic stem cell transplantation.
Conclusions MDWH can present with severe late- 
onset extraskeletal manifestations and thus should be 
reclassified and managed as cHH.
InTrOduCTIOn
Mutations in RMRP (mitochondrial RNA- 
processing endoribonuclease) cause a spectrum 
of autosomal recessive skeletal dysplasias with 
variable severity. These are currently classified as 
cartilage- hair hypoplasia (CHH, MIM #250250), 
anauxetic dysplasia-1 (ANXD-1, MIM #607095) 
and metaphyseal dysplasia without hypotrichosis 
(MDWH, MIM #250460). CHH is the most 
common presentation and is characterised by 
metaphyseal chondrodysplasia, hair hypoplasia, 
variable immunodeficiency and anaemia.1 2 In 
addition, patients with CHH have a high risk of 
cancer often resulting in premature death.3 Clinical 
manifestations of CHH vary considerably, even 
among siblings.1
ANXD represents the most severe end of the 
RMRP skeletal disease spectrum. It is a rare clinical 
entity with extremely severe short stature—tallest 
reported patient having a height of 74 cm at 16 
years—and can be caused by mutations in RMRP 
(ANXD-1) or POP1 (ANXD-2, MIM #602486).4–6 
In contrast to the mainly metaphyseal involvement 
seen in CHH and MDWH, vertebral bodies, pelvis 
and femoral epiphyses are also affected in ANXD. 
Apart from mild mental retardation, no extraskel-
etal manifestations have been reported. The oldest 
reported individual with ANXD-1 was 16 years 
old and no data on long- term disease course are 
available.
MDWH has been described as an isolated skel-
etal dysplasia in which hair hypoplasia, immunode-
ficiency and other extraskeletal manifestations are 
absent.7 Only 11 patients with MDWH have been 
previously reported, aged 5–11.5 years, and their 
clinical course beyond childhood is unknown.7–10
RMRP mutations in CHH, ANXD and MDWH 
differ and possibly have different biological conse-
quences, explaining distinct clinical presentation. 
Mutated RMRP in ANXD-1 results in normal 
processing of messenger RNA (mRNA), but 
impaired ribosomal RNA (rRNA) cleavage, while in 
CHH mRNA cleavage is also impacted.5 It has been 
proposed that rRNA and mRNA cleavage activity 
correlate with the degree of bone dysplasia and 
immunodeficiency, respectively.11
Our recent observation of severe bone marrow 
failure in an adult patient with MDWH- like presen-
tation in childhood and the large variability in 
disease severity in our CHH cohort2 12 prompted 
us to evaluate long- term outcome in patients with 
RMRP- associated skeletal dysplasia who have 
normal hair and absent extraskeletal manifestations 
in early childhood.
MeThOds
The index patient with MDWH was recruited to 
the study after diagnosis of agranulocytosis. The 
main study cohort involved 80 Finnish patients 
with genetically confirmed RMRP- related skeletal 
dysplasia, who were initially identified and under-
went interview, clinical examination, radiographic 
assessment and blood sampling in 1985–1991. A 
follow- up visit was conducted in 2011–2015, when 
patients were contacted and invited for an inter-
view, clinical assessment and blood tests. We also 
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Figure 1 growth in a patient with RMRP mutations, showing a typical 
pattern of growth failure progressing particularly during the first year of life 
and during puberty. the patient received growth hormone therapy from 6 
to 7 years of age, with no effect on growth.
Figure 2 Photographs and radiographs of the index patient. at 7 years, 
she had short stature with short limbs, valgus deformity of the knees and 
long, thick hair (a). Facial features, eye lashes and eye brows were normal 
(B). radiographs indicated no metaphyseal irregularity at the wrist or hand 
(c) or the knee (D), although subtle widening of the metaphyseal area was 
observed in the distal femur and proximal tibia. epiphyses in the hand (c) 
and knee (D) were small and flat. the patient developed significant scoliosis 
(e). Small and flat epiphyses were also seen at the hip (F) and by adulthood 
the femoral necks were short and the proximal femurs deformed (g).
collected health information for the 80 patients from two Finnish 
National Medical Databases. The Care Register for Health Care 
has since 1969 recorded the activities of health centres, hospitals 
and other institutions providing inpatient or home nursing care. 
Outpatient primary healthcare data were also derived from the 
Register of Primary Healthcare Visits, which covers all health 
centres in Finland since 2011. Database information included 
health service providers, dates of the visits, diagnoses, as well as 
diagnostic and therapeutic procedures. Based on database infor-
mation, we then collected and reviewed all patients’ detailed 
health records for inpatient and outpatient visits. Additionally, 
data on malignancies were obtained from the Finnish Cancer 
Register and mortality data from the Statistics Finland.
Birth lengths were compared with normal Finnish popula-
tion13 and SD scores (SDS), adjusted for gestational age, were 
used for analysis.
Statistical analysis was performed with IBM SPSS Statistics 
software V.23. The Fisher’s exact test and regression analyses 
were applied as appropriate.
resulTs
Case report
We identified a patient, followed at our institution for skeletal 
dysplasia with normal hair and absent extraskeletal manifesta-
tions. She was born at term measuring 3110 g (−1.0 SDS) and 
46 cm (−2.4 SDS). She developed progressive short stature 
(figure 1), for which growth hormone therapy at 6–7 years 
of age was ineffective. Skeletal dysplasia was suspected and 
confirmed at 7 years of age when radiographs revealed skeletal 
changes consistent with mainly epiphyseal dysplasia, particu-
larly in the hands and hips (figure 2). Very mild metaphyseal 
changes were also noticed, and they became less apparent with 
age (figure 2). She underwent several surgeries for leg deformity 
(valgus in knees, varus in feet) and also developed significant 
scoliosis. She had beautiful long thick hair (figure 2). In addi-
tion to a few episodes of otitis media, her childhood history of 
infections was remarkable only for severe varicella, molluscum 
contagiosum and skin warts. She had mild lymphopenia, but 
no further immunological evaluations were regarded indicated. 
At 19 years, a skeletal dysplasia gene panel revealed compound 
heterozygous variants in the RMRP gene, n.155G>T and n.-5de-
lins21 (NCBI reference sequence: NR_003051.3), confirming a 
RMRP- related skeletal dysplasia (figure 3).
Evaluation for fatigue at 18 years after an episode of rhinosi-
nusitis and conjunctivitis uncovered pancytopenia (haemoglobin 
93 g/L (normal range 117–155), platelets 109×109/L (normal 
range 150–360), white cell count 1.2×109/L (normal range 
3.4–8.2) and no detectable neutrophils. While anaemia and 
thrombocytopenia were mild and did not require therapy, agran-
ulocytosis persisted. The patient was lymphopenic (0.7×109/L 
(normal range 1.3–3.6), however, immunoglobulin levels 
appeared normal. Bone marrow examination revealed normal 
age- correlated cellularity (70%) but absent granulopoiesis and 
remarkable over- representation of lymphocytes (93% CD3+ 
cells, of which 60% were also CD8+). There was no clonal 
expansion of T cell receptor γ chain gene and the findings were 
not consistent with malignancy.
During the following year, agranulocytosis persisted despite 
treatment with filgrastim or prednisolone and the patient 
required multiple hospitalisations for bacterial and viral infec-
tions. She, therefore, received a haematopoietic stem cell trans-
plant (HSCT) from a human leukocyte antigen (HLA) -identical 
unrelated donor after a reduced- toxicity conditioning with treo-
sulfan, fludarabine and antithymocyte globulin. Neutrophils 
engrafted on day 20 post- HSCT, and bone marrow showed 
normal cellularity and total donor chimerism 2 months post- 
HSCT. She continued to experience viral and bacterial infec-
tions and was diagnosed with sinusoid obstruction syndrome 7 
months post- transplant. Despite normal bone marrow cellularity 
and full chimerism, her peripheral blood cell counts remain 
below normal limits at 11 months after HSCT, which potentially 
stems from multifactorial aetiology.
Cohort of Chh patients with normal hair
In the cohort of 80 patients with confirmed biallelic RMRP muta-
tions, we identified 10 subjects fulfilling the criteria for MDWH: 
in the preschool age, they presented with metaphyseal dysplasia, 
normal hair and absent extraskeletal manifestations (table 1). 
The remaining 70 patients had a clinical presentation typical 
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Figure 3 Sanger ecg of two different regions of the RMRP gene demonstrating (arrows) variants in the index patient and her parents.
for CHH. When clinical symptoms, radiographic features and 
laboratory results were compared, the 10 patients with MDWH 
did not differ significantly from the rest of the cohort, except 
for birth length. Their mean birth length was −2.03 SDS (95% 
CI −1.09 to −2.98 SDS), compared with the rest of the cohort 
with mean length of −3.06 SDS (95% CI −2.97 to −3.03 SDS) 
(p=0.031, B coefficient=0.647).
Among the 10 patients with MDWH, we identified eight 
patients who despite skeletal- only presentation during child-
hood, later developed extraskeletal manifestations (table 1). 
Their clinical course was unremarkable except for short- stature 
until the first extraskeletal symptoms at 7–17, 20, 43 and even 
50 years of age. Two patients developed malignancy (Hodgkin 
lymphoma and neuroendocrine carcinoma), and both deceased 
during chemotherapy. Another six patients developed signs of 
immunodeficiency including recurrent episodes of otitis media, 
rhinosinusitis and pneumonia, as well as bronchiectasis.
Two patients with MDWH are alive and well at 28 and 34 
years, with no extraskeletal manifestations apart from pollen 
allergy. One of them has been diagnosed with asymptomatic 
specific antibody deficiency, another has low levels of peripheral 
B cells (table 1).
Systematic laboratory assessments of immunological parame-
ters prior to the onset of extraskeletal manifestations have not 
been performed outside research visits, reflecting mild initial 
clinical course of the patients. Abnormal lymphocyte prolifera-
tive responses were detected in four patients before the develop-
ment of clinical immunodeficiency and malignancy.
dIsCussIOn
We tested our hypothesis that MDWH is not a separate disease 
entity by exploring the long- term outcome data in a large cohort 
on patients with RMRP mutations and skeletal dysplasia and 
demonstrated that subjects with MDWH can indeed develop 
late- onset immunodeficiency and malignancy, characteristic for 
CHH. Our index patient with biallelic RMRP mutations, skeletal 
dysplasia, normal hair and largely absent extraskeletal manifes-
tations in childhood, who developed severe bone marrow failure 
by early adulthood confirms the variable course and the impor-
tance of long- term surveillance.
We describe 10 Finnish patients from our large (n=80) 
CHH cohort who first presented with skeletal dysplasia only, 
thus fulfilling the criteria for MDWH. However, eight of them 
developed malignancy or clinical immunodeficiency later during 
follow- up. Thus, we suggest that MDWH represents cases of 
CHH with a risk for late- onset extraskeletal symptoms.
The 10 patients with MDWH presentation differed from the 
rest of the CHH cohort only by a less profound growth failure at 
birth. Although it would be tempting to associate milder growth 
failure with less severe extraskeletal manifestations, our present 
and previous studies contradict this by describing severe and 
even fatal complications of immunodeficiency in some patients 
with very mild growth failure.12
Genotype- phenotype correlations in cases with RMRP muta-
tions remain poorly understood.11 12 Possible explanations 
include polymorphisms in RMRP gene and non- allelic modi-
fiers.11 14 Almost all patients in our cohort were homozygous or 
heterozygous for the founder n.71A>G mutation. However, the 
patient with agranulocytosis was compound heterozygous for 
two very rare RMRP mutations n.155G>T and n.-5delins21. The 
n.155G>T has previously been identified in compound hetero-
zygous state with the founder mutation n.71G>A in a Finnish 
CHH patient.15 In addition, another variant in the same position, 
n.155G>C has been found in compound heterozygous state with 
a 15 bp duplication at position −24 in the promoter region in a 
patient with CHH, Omenn syndrome and CD8 lymphopenia.16 
Regarding the other mutation, almost the same insertion, 
differing from the identified variant only by two nucleotides, 
is a 20 bp duplication, n.-6_−25dup20 (n.5_−24dup20 using 
NR_003051.3 transcript), described by Hermanns et al.17 The 
RMRP variant n.-6_−25dup20 was found in two Belgian CHH 
patients (siblings, identical mutations) in compound heterozy-
gous state with both, n.91G>A and n.101C>T (n.92G>A and 
n.102C>T according to NR_003051.3) with unexplained func-
tional implication. Both patients had clinical diagnosis of CHH. 
The n.-6_−25dup20 duplication leads to reduced (but not 
absent) activity of the RMRP promoter compared with the wild 
type promoter, suggesting that RMRP transcription is decreased 
but not abolished.18
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Table 1 Clinical, laboratory and outcome characteristics of 10 patients fulfilling the criteria of metaphyseal dysplasia without hypotrichosis in early 
childhood
P 1 P 2 P 3 P 4 P 5 P 6 P 7 P 8 P 9 P 10
Mutation* n.71A>G/
71A>G
n.71A>G/
263G>T
n.71A>G/
71A>G
n.71A>G/
263G>T
n.71A>G/
71A>G
n.71A>G/
263G>T
n.71A>G/
71A>G
n.71A>G/
71A>G
n.71A>G/
71A>G
n.71A>G/
71A>G
Age at 
recruitment, years
4.3 0.6 6.6 10.2 14.2 15.3 17.1 26.4 23.8 34.3
Age at the latest 
follow- up, years
20.9 28.9 34.8 37.6 44.9 46.3 48.1 50.8 54.6 65.4
Duration of follow- 
up, years
16.6 28.3 28.2 27.4 30.7 31.0 31.0 24.4 30.8 31.1
Age at the first 
extraskeletal 
manifestation
20.7 N/A N/A 7–17 7–17 9 Adulthood 50.5 7–17 43.3
First extraskeletal 
manifestation
Hodgkin 
disease
Pollen 
allergy
Pollen 
allergy
Recurrent 
Sin
Recurrent Sin 
requiring sinus 
puncture
Recurrent 
Sin requiring 
sinus 
surgery at 8 
years
Recurrent 
Sin requiring 
sinus 
punctures at 
37 years
Neuroendocrine 
carcinoma
Recurrent Sin 
with polyposis 
requiring sinus 
punctures
Recurrent Sin, 
requiring sinus 
surgery at 61 
years
Other extraskeletal 
manifestations in 
adulthood
None None None Recurrent 
otitis media 
since 31 
years, skin 
warts, pollen 
allergy
Pollen allergy, 
bronchiectasis 
since 43 years
Pollen 
allergy
Skin warts Pollen allergy Maxillary 
polyposis 
requiring 
polypectomy at 
14 years
Recurrent 
pneumonia since 
55 years and 
bronchiectasis 
since 60 years
Severity of growth 
failure†
Severe Mild Mild Moderate Mild Mild Mild Mild Moderate Mild
Adult height 
group, cm
120–130 130–140 130–140 130–140 130–140 140–150 130–140 130–140 120–130 120–130
Lymphocyte 
subtypes‡
N/A Low 
CD19+at 
0.6 and 26 
years
Normal Normal Normal Low CD3+ 
and CD4+ 
at 44 years
Normal N/A Low CD3+, 
CD4+ and 
CD8+ at 36 
and 52 years
Normal
Lymphocyte 
proliferation§
N/A Abnormal at 
0.6 years
Normal Abnormal at 
10 years
N/A Abnormal at 
2 years
Abnormal at 
7 years
Abnormal at 12 
years
Abnormal at 
10 years
N/A
IgA, M and G 
levels¶
N/A Normal Normal Normal Normal Normal Normal Normal Normal Normal IgA and 
IgG, low IgM at 
60 years
SAD** N/A N/A Yes, at 32 
years
N/A N/A None at 44 
years
None at 45 
years
N/A Yes, at 52 years None at 62 years
Outcome Died at 20 
years during 
cancer 
treatment
Alive Alive Alive Alive Alive Alive Died at 50 years 
during cancer 
treatment
Alive Alive
*Reference sequence: NR_003051.3.
†Growth failure classified based on CHH- specific growth charts as described in.20
‡Lymphocyte subtypes included CD3+, CD4+, CD8+, CD19+ and CD16/56+ absolute cell numbers measured by flow cytometry as described in.2
§Lymphocyte proliferation measured to PHA, ConA and PWM as described in.20
¶Measured as described in.2
**Specific antibody deficiency was defined as inadequate antibody response to Pneumovax: a fourfold rise in antibody titres and post- immunisation antibody levels ≥0.35 µg/mL 
to <70% of serotypes, measured as described previously in.2
CHH, cartilage- hair hypoplasia; NA, not available; PHA, phytohaemagglutinin; SAD, specific antibody deficiency.
The spectrum of diseases caused by RMRP mutations incorpo-
rates skeletal dysplasia of various severity and diverse extraskel-
etal manifestations. Clinical classification into MDWH, CHH 
and ANXD is based on the degree of skeletal dysplasia, the pres-
ence of hair hypoplasia and other extraskeletal manifestations. 
However, no long- term follow- up data have until now been 
published for patients with RMRP mutations. Therefore, it has 
been unclear, whether MDWH or ANXD patients develop clin-
ically significant immunodeficiency or malignancies later in life. 
Our index patient had skeletal characteristics overlapping with 
ANXD (significant hip and spine involvement) and the findings 
were not typical for CHH or MDWH. In contrast, the patients 
with MDWH presented with radiographic findings typical for 
CHH.19
Patients with CHH present with extremely variable clinical 
features, and even short- stature can be absent in childhood.11 In 
the largest clinical series of 108 individuals with CHH, hair was 
normal in 7% and no susceptibility to infections could be shown 
in 44% of the patients.1 Thus, some of the patients could be 
designated to have MDWH. On the other hand, severe growth 
failure up to −11 SD that is in the range of ANXD has also been 
reported in subjects with CHH,1 raising the question of whether 
MDWH, CHH and ANXD are actually all the same disease of 
variable severity.
Labelling mildly affected patients with RMRP mutations as 
having MDWH can negatively affect the management and 
follow- up of such patients, blunting the clinicians away from 
potential extraskeletal complications. Our study demonstrates 
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the development of clinically significant immunodeficiency and 
malignancies in previously asymptomatic short- statured patients. 
Therefore, careful and regular clinical assessment should be 
organised for individuals with RMRP mutations even in the 
absence of extraskeletal manifestations on presentation.
We demonstrate serious late- onset extraskeletal manifestations 
in patients with MDWH and suggest that these cases should be 
reclassified and managed as CHH.
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